Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 8/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PKLR | P30613 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381546 | 0.81 | KDM4E (0.46) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL18007621 | 0.81 | CA1 (0.62) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27636487 | 0.79 | KDM4E (0.44) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL51046 | 0.77 | MAPK1 (0.68) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL29663898 | 0.77 | MAPK1 (0.68) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14405010 | 0.77 | KDM4E (0.42) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL4325354 | 0.76 | TSHR (0.54) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30871757 | 0.74 | LMNA (0.55) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL11871336 | 0.73 | ALDH1A1 (0.50) | MAPTKDM4EALDH1A1KMT2AMAPK1 | |
| SCHEMBL22116812 | 0.73 | KDM4E (0.51) | MAPTKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107805223-A | A kind of synthetic method of the sulfonic acid chloride of quinoxaline 5 | 广东莱佛士制药技术有限公司 | 2018-03-16 | — | — | CN | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| WO-2025233901-A1 | ACTIVATORS OF PYRUVATE KINASE ISOFORM M2 AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-13 | — | — | WO | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| CN-115768750-A | GCN2 modulator compounds | 阿莱斯塔治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| EP-4107146-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2022-12-28 | — | — | EP | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| CN-1863782-A | 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-15 | — | — | CN | disclosed |
| CN-1863781-A | 2- (quinoxalin-5-ylsulfonamido) -benzamide compounds as cholecystokinin 2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-11-15 | — | — | CN | disclosed |
| EP-1651622-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | Janssen Pharmaceutica N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2006036670-A1 | SULFONAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069286-A1 | Sulfonamide compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-03-30 | — | — | US | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016897-A1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | MAPT 4614/4885KDM4E 3979/4885ALDH1A1 4260/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | MAPT 3092/4885KDM4E 3408/4885ALDH1A1 4030/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | MAPT 4849/4885KDM4E 3167/4885ALDH1A1 4604/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | MAPT 4633/4885KDM4E 3681/4885ALDH1A1 4427/4885 |
| US-20060069286-A1 | Sulfonamide compounds | CCKAR, CCKBR, TAS1R2 | MAPT 4574/4885KDM4E 3780/4885ALDH1A1 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.